FAST NEWS: Legend Biotech Halts Trials for LB1901 CAR-T Therapy Drug
The latest: Legend Biotech Corp. (LEGN.US) announced that the Phase 1 clinical trial for its LB1901 drug has been put on hold. LB1901 is the company’s autologous chimeric antigen receptor…
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK -
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
1548.HK LEGN.US
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
